vs
Side-by-side financial comparison of BJs RESTAURANTS INC (BJRI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $355.4M, roughly 1.8× BJs RESTAURANTS INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 3.6%, a 30.9% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 3.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 2.6%).
BJ's Restaurants Inc. operates a chain of casual dining restaurants across the United States. Its menu features signature deep-dish pizzas, craft beers, handcrafted cocktails, and a wide range of American comfort food. The brand primarily serves family groups, friend gatherings, and casual diners seeking affordable, high-quality meals in a relaxed, welcoming in-store environment.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BJRI vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $355.4M | $622.0M |
| Net Profit | $12.6M | $214.2M |
| Gross Margin | 74.5% | — |
| Operating Margin | 3.1% | 62.4% |
| Net Margin | 3.6% | 34.4% |
| Revenue YoY | 3.2% | 4.8% |
| Net Profit YoY | -24.2% | 2.9% |
| EPS (diluted) | $0.58 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $355.4M | $622.0M | ||
| Q3 25 | $365.6M | $609.3M | ||
| Q2 25 | $348.0M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $325.7M | $593.6M | ||
| Q3 24 | $349.9M | $564.7M | ||
| Q2 24 | $337.3M | $537.3M | ||
| Q1 24 | — | $568.0M |
| Q4 25 | $12.6M | $214.2M | ||
| Q3 25 | $22.2M | $288.2M | ||
| Q2 25 | $13.5M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $-2.9M | $208.2M | ||
| Q3 24 | $17.2M | $544.0M | ||
| Q2 24 | $7.7M | $102.0M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | 74.5% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 75.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 73.4% | — | ||
| Q3 24 | 74.3% | — | ||
| Q2 24 | 74.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.1% | 62.4% | ||
| Q3 25 | 5.8% | 70.1% | ||
| Q2 25 | 4.3% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | -0.8% | 60.9% | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 2.4% | 50.2% | ||
| Q1 24 | — | -13.0% |
| Q4 25 | 3.6% | 34.4% | ||
| Q3 25 | 6.1% | 47.3% | ||
| Q2 25 | 3.9% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | -0.9% | 35.1% | ||
| Q3 24 | 4.9% | 96.3% | ||
| Q2 24 | 2.3% | 19.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | $0.58 | $0.49 | ||
| Q3 25 | $0.97 | $0.67 | ||
| Q2 25 | $0.58 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $-0.13 | $0.46 | ||
| Q3 24 | $0.72 | $1.21 | ||
| Q2 24 | $0.32 | $0.23 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.8M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $366.2M | $9.7B |
| Total Assets | $1.0B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.8M | $618.7M | ||
| Q3 25 | $26.0M | $938.9M | ||
| Q2 25 | $19.0M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $18.4M | $929.0M | ||
| Q3 24 | $16.2M | $950.1M | ||
| Q2 24 | $18.8M | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $60.5M | $8.9B | ||
| Q2 25 | $85.5M | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $66.5M | $7.6B | ||
| Q3 24 | $63.5M | $7.6B | ||
| Q2 24 | $58.0M | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $366.2M | $9.7B | ||
| Q3 25 | $386.6M | $9.6B | ||
| Q2 25 | $371.5M | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $376.2M | $10.3B | ||
| Q3 24 | $386.5M | $10.3B | ||
| Q2 24 | $375.4M | $9.8B | ||
| Q1 24 | — | $9.9B |
| Q4 25 | $1.0B | $19.6B | ||
| Q3 25 | $1.0B | $19.3B | ||
| Q2 25 | $1.0B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $1.0B | $18.2B | ||
| Q3 24 | $1.0B | $18.0B | ||
| Q2 24 | $1.0B | $17.7B | ||
| Q1 24 | — | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.16× | 0.93× | ||
| Q2 25 | 0.23× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.18× | 0.74× | ||
| Q3 24 | 0.16× | 0.74× | ||
| Q2 24 | 0.15× | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $62.3M | $702.6M | ||
| Q2 25 | $4.6M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $27.3M | $742.5M | ||
| Q3 24 | $20.2M | $703.6M | ||
| Q2 24 | $22.3M | $658.2M | ||
| Q1 24 | — | $664.6M |
| Q4 25 | — | — | ||
| Q3 25 | $41.9M | — | ||
| Q2 25 | $-12.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $735.0K | — | ||
| Q2 24 | $448.0K | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | -3.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | 6.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 2.80× | 2.44× | ||
| Q2 25 | 0.34× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.18× | 1.29× | ||
| Q2 24 | 2.89× | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BJRI
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
